I 型糖尿病 z-bo 2020-09-17 349

　　Researchers at St. Louis University School of Medicine in St. Louis, USA, recently discovered a new way to prevent type I diabetes, and the experiment was successful in mice. Type I diabetes is a chronic autoimmune disease, and many types of immune T cells have been confirmed to participate in the development and regulation of type I diabetes. The role of TH17 cells, one of the T cells, is controversial. In order to understand the specific role of TH17 cells, researchers at St. Louis University School of Medicine chose the high-affinity ligand SR1001, which selectively stimulates two important nuclear receptors that can regulate the development and function of TH17 cells. I synthesized it. OR alpha and ROR gamma achieve the purpose of inhibiting the differentiation and function of TH17 cells. In non-obese diabetic mice, after continuous injection of SR1001,

　　"The experiment reduced the incidence of type I diabetes to zero, while the incidence of type I diabetes in the control group was 70%. Turns out I did it! Dr. Burris of the research group did not observe that the mice in the experimental group developed type I diabetes after the injection, even if the islet B cells were significantly damaged before the injection. In the later stage of injection, even if significant immune infiltration was observed in the pancreas sections of the mice, compared with the control group, the retained islet B cells were significantly higher, and the expression of insulin in the cells was also significantly increased. I'm. These results indicate that the inhibition of ROR function plays an important role in the protection of islet B cells in an autoimmune environment.

　　Why does SR1001 have this effect? Follow-up studies have shown that SR1001 inhibits the immune invasion of the pancreas, reduces the formation of autoimmune antibodies against pancreatic islet B cells, and more importantly, it interferes with the expression of various inflammatory cytokines. Dr. Burris believes that ROR inhibitors can slow the progression of type I diabetes and even replace insulin therapy. It has been found that the development of ROR inhibitors provides other possibilities for the prevention or treatment of type I diabetes.